Orforglipron, a Daily GLP-1 Pill, Cut Weight in Adults With Diabetes

CATEGORY: METABOLIC & BLOOD SUGAR

The GLP-1 drugs that reshaped weight loss have mostly come as weekly injections. A pill would change who can reach them. In a trial of 1,613 adults who had both obesity and type 2 diabetes, the once-daily tablet orforglipron cut body weight by up to 9.6% over 72 weeks, against 2.5% for a placebo pill, while also pulling down blood sugar.¹ No needle, no refrigeration, no timing it around food or water.

A Pill That Acts Like the Injections

Orforglipron mimics GLP-1, a gut hormone that quiets appetite and steadies blood sugar after eating. Semaglutide and tirzepatide do the same, but they’re injected, and the one oral GLP-1 already sold must be taken on an empty stomach with strict rules. Orforglipron is a small molecule, sturdy enough to swallow as an ordinary tablet. That’s why regulators’ approval of it in April 2026 drew notice: for people with diabetes who won’t or can’t inject, an equally simple pill widens the door.

Three Doses, Randomly Assigned

The trial spanned adults with obesity or overweight plus type 2 diabetes, average starting blood sugar around 8%. A computer sorted them into one of three orforglipron doses or a placebo, and neither they nor their doctors knew which. Over 72 weeks the results tracked the dose. Weight fell 5.1% on the lowest dose and 9.6% on the highest, versus 2.5% on placebo.¹ HbA1c, the three-month blood sugar average, dropped up to 1.8 percentage points against 0.1 on placebo, and most people on the drug finished under the 6.5% mark that signals good control. A larger companion trial in people without diabetes found weight loss reaching 11.2%.²

The Familiar GLP-1 Trade-Off

The side effects are the ones this drug class is known for: nausea, vomiting, diarrhea and constipation, mostly mild to moderate. They pushed 6% to 10% of people off the drug, compared with 4% on placebo.¹ One honest limit: weight loss on a pill you swallow tends to trail the strongest injections, so a tablet is not automatically the most powerful option. It’s the most reachable one. For a person weighing whether to start any of these medicines, the choice between a shot and a pill is now a real choice rather than a foregone one.

Key Takeaways

• An oral GLP-1 pill lowered weight by up to 9.6% and HbA1c by up to 1.8 points over 72 weeks in adults with obesity and type 2 diabetes.
• Because it’s a swallowable tablet with no food or timing rules, it removes the injection barrier that keeps some people from this drug class.
• Gastrointestinal side effects were common and led 6% to 10% of users to stop, versus 4% on placebo.
• Pill-based weight loss generally runs below the strongest injectables, so this is about access more than maximum effect.

References

1. Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927–2944. link
2. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796–1806. link